Neil D. Gross, MD, FACS, discusses how treatment with neoadjuvant cemiplimab followed by surgery with curative intent prolonged event-free survival in patients with stage II to IV cutaneous squamous cell carcinoma, adding that these outcomes warrant further investigation in a randomized setting.
Neoadjuvant cemiplimab followed by surgery resulted in favorable survival outcomes for patients with resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), addressing an area of unmet need, explained Neil D. Gross, MD, FACS, of MD Anderson.
A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.